stockportfolio.pro
Stocks / IMNM vs MLYS
IMNM vs MLYS
Immunome, Inc. and Mineralys Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Immunome, Inc. (IMNM) | Mineralys Therapeutics, Inc. (MLYS) | |
|---|---|---|
| Market cap | $2.1B | $2.1B |
| Revenue (latest FY) | $6.94M | $0 |
| Net income (latest FY) | $-212.39M | $-154.65M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | -3060.0% | — |
| Return on equity | -33.5% | -23.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open IMNM — free Open MLYS — freeFrequently asked questions
Which is bigger, IMNM or MLYS?
Mineralys Therapeutics, Inc. is larger by market capitalization — $2.1B versus $2.1B.
Which grows faster, IMNM or MLYS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.